Hirtle Callaghan & Co’s Bristol-Myers Squibb BMY Stock Holding History

Hirtle Callaghan & Co’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-14,200	Closed	-$766K	–	155
2016 Q3	$766K	Hold	14,200	–	–	0.16%	39
2016 Q2	$1.04M	Hold	14,200	–	–	0.19%	29
2016 Q1	$907K	Buy	+14,200	New	+$896K	0.17%	32
2015 Q1	–	Sell	-21,401	Closed	-$1.27M	–	59
2014 Q4	$1.27M	Hold	21,401	–	–	0.29%	56
2014 Q3	$1.09M	Hold	21,401	–	–	0.18%	64
2014 Q2	$1.04M	Hold	21,401	–	–	0.14%	92
2014 Q1	$1.11M	Sell	21,401 -100	-0.5%	-$5.32K	0.18%	70
2013 Q4	$1.15M	Sell	21,501 -100	-0.5%	-$5.09K	0.15%	74
2013 Q3	$1M	Buy	+21,601	New	+$948K	0.16%	75

Other funds holding BMY

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Hirtle Callaghan & Co's BMY Position: Q4 2016 in Review

Hirtle Callaghan & Co sold out of Bristol-Myers Squibb (BMY) in Q4 2016, closing a stake of 14,200 shares — an estimated $766K sold.

Hirtle Callaghan & Co first reported a position in BMY in Q3 2013 and held it in 9 quarters. The position peaked at $1.27M in Q4 2014. 1,601 funds tracked by Wall St. Rank hold BMY as of Q4 2016.

Hirtle Callaghan & Co reported no remaining Bristol-Myers Squibb position as of Q4 2016 after selling out during the quarter.
Hirtle Callaghan & Co sold 14,200 Bristol-Myers Squibb shares in Q4 2016, an estimated $766K.
Hirtle Callaghan & Co first reported a position in Bristol-Myers Squibb in Q3 2013 and held it in 9 quarters.
Hirtle Callaghan & Co's Bristol-Myers Squibb position peaked at $1.27M in Q4 2014.
1,601 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2016.

Based on Hirtle Callaghan & Co's 13F filing for Q4 2016, filed 31 Jan 2017.